- Home
- GDO vs TCRX Comparison
GDO vs TCRX Comparison
Compare GDO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDO | TCRX |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.5M | 75.1M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDO | TCRX |
|---|---|---|
| Price | $10.90 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 23.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $10.52 | $0.88 |
| 52 Week High | $12.15 | $2.57 |
Technical Indicators
Market Signals| Indicator | GDO | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 48.37 |
| Support Level | $10.92 | $0.93 |
| Resistance Level | $11.15 | $1.21 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.87 | 28.00 |
Price Performance
Historical ComparisonAbout GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.